ICICI Securities: GSK Pharma - Analyst Call Highlights

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..ICICI Securities Report.GlaxoSmithKline Pharmaceuticals Ltd. held a virtual analyst meet to discuss the company’s performance.We cover the highlights below:Company believes its key brands and therapies would continue to grow over the next five years.Company has witnessed that most of its key brands have outpaced their respective industries and gained market share.Vaccines remains an important growth area followed by respiratory. It will also invest in therapies like oncology but that would take time to scale up.Vaccines segment contributes approximately 23% of revenue and is expected to grow in double digits. It’s imported and has lower margin than the company but it would be supported by cost optimisation.Company has received approval for Augmentin ES600, Trelegy and Fluarix Tetra and has filed for Shingrix, Rotarix liquid oral vaccine and Nucala liquid pediatric indication to support growth over long term.In the near term, it is focusing on Nucala and Menveo..Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint. .Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

ICICI Securities: GSK Pharma - Analyst Call Highlights

ICICI Securities: GSK Pharma - Analyst Call Highlights

Choose a plan